Save up to 30% on Elsevier print and eBooks with free shipping. No promo code needed.
Save up to 30% on print and eBooks.
Epigenetic Biomarkers and Diagnostics
1st Edition - December 4, 2015
Editor: Jose Luis Garcia-Gimenez
Language: English
Hardback ISBN:9780128018996
9 7 8 - 0 - 1 2 - 8 0 1 8 9 9 - 6
eBook ISBN:9780128019214
9 7 8 - 0 - 1 2 - 8 0 1 9 2 1 - 4
Epigenetic Biomarkers and Diagnostics comprises 31 chapters contributed by leading active researchers in basic and clinical epigenetics. The book begins with the basis of epigeneti…Read more
Purchase options
LIMITED OFFER
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code is needed.
Epigenetic Biomarkers and Diagnostics comprises 31 chapters contributed by leading active researchers in basic and clinical epigenetics. The book begins with the basis of epigenetic mechanisms and descriptions of epigenetic biomarkers that can be used in clinical diagnostics and prognostics. It goes on to discuss classical methods and next generation sequencing-based technologies to discover and analyze epigenetic biomarkers. The book concludes with an account of DNA methylation, post-translational modifications and noncoding RNAs as the most promising biomarkers for cancer (i.e. breast, lung, colon, etc.), metabolic disorders (i.e. diabetes and obesity), autoimmune diseases, infertility, allergy, infectious diseases, and neurological disorders.
The book describes the challenging aspects of research in epigenetics, and current findings regarding new epigenetic elements and modifiers, providing guidance for researchers interested in the most advanced technologies and tested biomarkers to be used in the clinical diagnosis or prognosis of disease.
Focuses on recent progress in several areas of epigenetics, general concepts regarding epigenetics, and the future prospects of this discipline in clinical diagnostics and prognostics
Describes the importance of the quality of samples and clinical associated data, and also the ethical issues for epigenetic diagnostics
Discusses the advances in epigenomics technologies, including next-generation sequencing based tools and applications
Expounds on the utility of epigenetic biomarkers for diagnosis and prognosis of several diseases, highlighting the study of these biomarkers in cancer, cardiovascular and metabolic diseases, infertility, and infectious diseases
Includes a special section that discusses the relevance of biobanks in the maintenance of high quality biosamples and clinical-associated data, and the relevance of the ethical aspects in epigenetic studies
specialists in epigenetics, researchers in genetics, biology, physiology, biomedicine, biotechnology, bioinformatics, physicians from diverse specialties (oncology, endocrinology, pediatrics, pathology, andrology, gerontology, nutrition, etc.), biotech companies interested in developing new biomarkers, graduate students new to epigenetics
List of Contributors
Preface
Chapter 1. Epigenetic Biomarkers: New Findings, Perspectives, and Future Directions in Diagnostics
1. Introduction
2. Epigenetic Mechanisms
3. Epigenetic Biomarkers and In Vitro Diagnostics
4. Epigenetic Biomarkers and the Clinical Laboratory
5. Epigenetic Biomarkers: An Overview of Recent Advances
6. Epigenetics: Perspective of Implantation in Clinical Laboratories
7. Perspectives of Epigenetics in Diagnostics
List of Abbreviations
Chapter 2. The Importance of Biobanks in Epigenetic Studies
1. Biobanks
2. Biobanks in Biomedical Research
3. Epigenetics and Biobanking
4. Conclusions
List of Abbreviations
Chapter 3. Epigenetic Mechanisms as Key Regulators in Disease: Clinical Implications
1. Introduction
2. Epigenetics and Metabolism Intersection
3. Lifestyle, Nutrition, and Physical Activity in Epigenetic Regulation
16. Future of DNA Methylation in Clinical Applications
List of Abbreviations
Chapter 9. Pyrosequencing and Its Application in Epigenetic Clinical Diagnostics
1. Introduction
2. Detection of Epigenetic Changes By Pyrosequencing: DNA Methylation
3. Pyrosequencing and the Assessment to miRNAs
4. Conclusions
Glossary
List of Abbreviations
Chapter 10. Mass Spectrometry for the Identification of Posttranslational Modifications in Histones and Its Application in Clinical Epigenetics
1. Introduction
2. MS Analysis of hPTMs
3. Toward Clinical Applications of MS Analysis of hPTMs
4. Conclusions and Perspectives
List of Abbreviations
Chapter 11. High-Throughput Analysis of Noncoding RNAs: Implications in Clinical Epigenetics
1. Introduction
2. ncRNAs: Definitions and Innovative Technologies for Their Analysis
3. How the Epigenome Controls ncRNAs and How ncRNAs Control the Epigenome
4. ncRNAs and Epigenetics: Clinical Relevance
5. Conclusions and Future Perspectives
Glossary
List of Abbreviations
Chapter 12. Circulating Noncoding RNAs as Clinical Biomarkers
1. Introduction
2. MicroRNAs
3. Long Noncoding RNAs
4. Circular RNAs
5. Resources for Circulating RNAs
6. Conclusion and Future Perspective
List of Abbreviations
Chapter 13. DNA Methylation Biomarkers in Lung Cancer
1. Introduction
2. Methylation
3. Epigenetic-Associated Regulatory Elements
4. DNA Methylation in Cancer
5. DNA Methylation in Lung Cancer
6. Conclusions
List of Abbreviations
Chapter 14. DNA Methylation Alterations as Biomarkers for Prostate Cancer
1. Introduction
2. The Aberrant DNA Methylation Landscape of PCa
3. Promoter Hypermethylation in PCa
4. Hypomethylation in PCa
5. DNA Methylation-Based Markers for PCa Detection, Management, and Risk Estimation
6. Cancer Detection and Diagnosis
7. Prognosis and Prediction of Response to Therapy
8. Conclusions and Perspectives
Glossary
List of Abbreviations
Chapter 15. DNA Methylation in Breast Cancer
1. Introduction
2. Major Milestones in Breast Cancer and DNA Methylation Research
3. DNA Methylation
4. DNA Methylation as a Therapeutic Target
5. Concluding Remarks and Future Prospects
List of Abbreviations
Chapter 16. DNA Methylation in Obesity and Associated Diseases
1. Introduction
2. An Overview of Epigenetics: Focus on DNA Methylation
3. Environmental and Lifestyle Factors Influencing DNA Methylation
4. DNA Methylation Pattern and Obesity Susceptibility
5. Epigenetics as a Link between Obesity and Its Codiseases
6. DNA Methylation as Biomarker of Disease
7. Epigenetic Drugs and Functional Foods for Overcoming Metabolic Diseases
8. Conclusion
List of Abbreviations
Chapter 17. DNA Methylation Biomarkers in Asthma and Allergy
1. Introduction
2. Allergic Diseases: Phenotypes and Genes
3. Why Has Epigenetics Become a Buzz Word in Allergic Disease?
4. What Have We learned So Far from Allergic Disease Epigenetics?
5. Conclusion: Where Is the Field Going?
List of Abbreviations
Chapter 18. DNA Methylation for Prediction of Adverse Pregnancy Outcomes
1. Introduction
2. Epigenetics
3. Epigenetic Mechanisms
4. Regulation of Gene Expression by Epigenetic Mechanisms
5. Epigenetic Changes during the Mammalian Life Cycle
6. DNA Methylation during Embryonic Development
7. Maternal Nutrition, DOHaD, and Epigenetics
8. Epigenetic Regulation in the Placenta and Adverse Pregnancy Complications
9. Conclusion and Future Prospects
Glossary
List of Abbreviations
Chapter 19. Epigenetics in Infectious Diseases
1. Introduction
2. miRNA Profiles
3. DNA Methylation Patterns
4. Histone marks
5. Concluding remarks
Glossary
List of Acronyms and Abbreviations
Chapter 20. DNA Methylation in Neurodegenerative Diseases
1. Introduction
2. DNA Methylation and the CNS
3. Alzheimer’s Disease
4. Parkinson’s Disease
5. Amyotrophic Lateral Sclerosis
6. Huntington’s Disease
7. Fragile X-Associated Tremor/Ataxia Syndrome
8. Friedreich Ataxia
9. Spinocerebellar Ataxia 7
10. Conclusion
List of Abbreviations
Chapter 21. The Histone Code and Disease: Posttranslational Modifications as Potential Prognostic Factors for Clinical Diagnosis
1. Introduction
2. Histone Modifications and Disease
3. Conclusions
Glossary
List of Abbreviations
Chapter 22. Histone Posttranslational Modifications and Chromatin Remodelers in Prostate Cancer
1. Introduction
2. Epigenetic-Based Markers for PCa Detection, Management, and Risk Estimation
3. Epigenetic Silencing as a Therapeutic Target in PCa
4. Conclusion
Glossary
List of Abbreviations
Chapter 23. Histone Posttranslational Modifications in Breast Cancer and Their Use in Clinical Diagnosis and Prognosis
1. Histone Marks and the Epigenetic Landscape
2. Breast Cancer Subtypes, Hormonal Dependence, and Epigenetic Regulation
3. Epigenetic Factors in Mammary Gland Development and Cancer
4. Epigenetic Complexes as Mutational Targets in Luminal Breast Cancer
5. Epigenetic Modifications as Biomarkers for Treatment Sensitivity and Outcome
6. Epigenetic Modifiers as Potential Drug Targets in Cancer
7. Conclusive remarks
Glossary
List of Abbreviations
Chapter 24. Histone Variants and Posttranslational Modifications in Spermatogenesis and Infertility
1. Introduction
2. Histone Variants and their Role in Infertility
3. The Effects of Histone PTMs
4. Brief Overview of the Role of Spermiogenesis-Specific Nuclear Basic Proteins: TNPs and Protamines in Infertility
5. Can Histone Variants be Used as Biomarkers for Infertility?
6. Closing Remarks
Glossary
List of Abbreviations
Chapter 25. Circulating Histones and Nucleosomes as Biomarkers in Sepsis and Septic Shock
1. Introduction
2. Epidemiology and Clinical Features of Sepsis, Severe Sepsis, and Septic Shock
3. Genetics, Epigenetics, and Molecular Pathways Underlying Sepsis
4. Extracellular Nucleosomes and Histones and Their Role in the Physiopathology of Sepsis and Septic Shock
5. Circulating Histones as Biomarkers of Prognosis and Treatment Monitoring
6. Therapeutic Approaches to Antagonize Histone-Mediated Toxicity
7. Conclusions
Glossary
List of Abbreviations
Chapter 26. Chromatin Landscape and Epigenetic Signatures in Neurological Disorders: Emerging Perspectives for Biological and Clinical Research
1. Introduction
2. The Involvement of Epigenetic Modifications in HD
3. The Involvement of Epigenetic Modifications in ALS
4. Conclusions and Future Perspectives
Glossary
List of Abbreviations
Chapter 27. MicroRNA Deregulation in Lung Cancer and Their Use as Clinical Tools
1. Introduction to Noncoding RNA in Human Cell Physiology
2. miRNA Biology and Mechanism of Action
3. miRNA Alteration in Lung Cancer Progression
4. miRNA-Based Biomarkers for Lung Cancer Diagnosis, Prognosis, and Treatment
5. Interplay between Genetics and Epigenetics in miRNA Regulation and Lung Cancer
6. miRNA-Based Anticancer Therapy
7. Concluding Remarks
List of Abbreviations
Chapter 28. Circulating Nucleic Acids as Prostate Cancer Biomarkers
1. Introduction—The Urgent Requirement for New Prostate Cancer Biomarkers
2. Circulating miRNAs as Biomarkers
3. Circulating mRNAs as Biomarkers
4. Cell-Free DNAs as Biomarkers
5. Conclusions
List of Abbreviations
Chapter 29. MicroRNAs in Breast Cancer and Their Value as Biomarkers
1. Introduction
2. Global Deregulation of miRNAs in Cancer
3. The Biological Significance of miRNAs in Breast Cancer Development
4. Genetic Variants in miRNAs and Their Binding Sites
5. Acquired Genomic and Epigenomic Changes Affecting miRNAs
6. miRNAs as Regulators of the DNA Damage Response
7. DNA Repair Genes as Targets of miRNAs: A Bridge toward Personalized Treatment?
8. miRNAs as Prognostic Biomarkers
9. The Use of miRNAs in Screening for Early Breast Cancer Development
10. Conclusions
Glossary
List of Abbreviations
Chapter 30. MicroRNAs in Bone and Soft Tissue Sarcomas and Their Value as Biomarkers
1. Introduction
2. miRNAs in Bone Sarcomas
3. miRNAs in Soft Tissue Sarcomas
4. Circulating miRNAs in Bone and Soft Tissue Sarcomas
5. Conclusions
list of Abbreviations
Chapter 31. miRNAs in the Pathophysiology of Diabetes and Their Value as Biomarkers
1. Introduction
2. miRNAs Regulating Pancreatic β-Cell Function and Insulin Secretion
3. miRNAs in Insulin Target Tissues: Liver, Skeletal Muscle, and Adipose Tissue
4. miRNA Responses to Antidiabetic Therapies
5. Pharmacological Targeting of miRNAs in Diabetes
6. Circulating miRNAs as Promising Clinical Biomarkers for Diabetes
7. Conclusion
List of Abbreviations
Index
No. of pages: 696
Language: English
Edition: 1
Published: December 4, 2015
Imprint: Academic Press
Hardback ISBN: 9780128018996
eBook ISBN: 9780128019214
JG
Jose Luis Garcia-Gimenez
Dr. Garcia-Gimenez is a Senior Researcher at the Consortium Center for Biomedical Network Research, the Spanish Institute of Health Carlos III (ISCIII), and the INCLIVA Biomedical Research Institute, in the Dept. of Physiology at the Medicine and Dentistry School at the University of Valencia, Spain. Dr. García-Giménez is founder and CEO of EpiDisease S.L. (Spin-Off of CIBER-ISCIII), which develops the technology based on the patent EP15382319.0, currently in national phases (USTPO, EPO, CIPO and SIPO). EpiDisease received NEOTEC funds from CDTI and the Seal of Excellence from the European Commission in the SME Instrument Phase II H2020. Dr. García-Giménez has received 7 scientific and entrepreneurship national and international awards, including the National Award for Young Entrepreneurs in 2013 (awarded by the Spanish Ministry of Health) and the European Young Researcher from the Free Radical Research Society in 2009 and more recently the Eureka Innovation and Entrepreneurship Award in Melbourne (Australia). Dr. Garcia-Gimenez is a researcher at the University of Valencia. He is early in his career, but has been noticed as an up-and-coming authority in epigenetic biomarker research as it relates to disease, stress, and exercise.
Affiliations and expertise
CIBER Enfermedades Raras, Centre for Biomedical Research on Rare Diseases, University of Valencia, Spain
Read Epigenetic Biomarkers and Diagnostics on ScienceDirect